“Funding new globally applicable markets with explosive growth is key to start-up investing. Once such market which will be huge in 2012 is that of “Big Data,” deriving business insights from previously unmanageable amounts of data. Some 90% of the world’s data have been generated in the past two years. Processing the data faster or combining the data to create better information represents an enormous opportunity for start-ups across the globe. EMC, IBM and HP have all recently announced massive investments in this area for 2012 — a cue for talented entrepreneurs to invest and package products from Big Data.” – The World in 2012, The Economist
Finally, a Comprehensive Big Data Solution for Life Sciences Professionals
The Relay Innovation Engine aggregates scientific and market data in real-time and provides competitive business intelligence to life sciences professionals. The Relay Innovation Engine powers Business Development Live! (BD Live!) for Biotechnology & Pharmaceutical companies, and Technology Transfer Live! (TT Live!) for University Technology Transfer Offices.
The Relay Innovation Engine analytics platform enables identification of scientific and market trends in drug development in a way never before captured or visualized.
Relay provides decision support and data interaction through a software-as-a-service platform to both business and research professionals in the life sciences industry.
A Comprehensive Approach to Sourcing and Evaluating Biomedical Technologies
As later stage drug candidates become more difficult to in-license, focus has shifted toward earlier stage candidates, often based on university technology. The current method for identifying in-licensing opportunities is time-consuming, labor-intensive, and often subject to preferences of the business development/licensing professional conducting the search.
Relay Technology Management augments business development efforts in both breadth and depth using a web-based analytics approach to identify promising drug candidates from academic research institutions and early-stage biotechnology companies. Relay’s algorithms include multiple factors that contribute to the value of early-stage technologies, such as intellectual property, commercial potential, and scientific standing. The database evaluates pre-clinical technologies from over 500 academic research institutes, and phase II/III clinical trial candidates from 2500 biotechnology companies around the world.
The Relay methodology has been validated both retrospectively and prospectively. For example, the Relay criteria were applied to a major therapeutic category over the course of 8 months, and rapidly identified 6 of the 10 major licensing opportunities during that period. In contrast to services which provide simple data searching, the Relay approach incorporates key decision support metrics such strength of intellectual property, market potential, and scientific trends. These features allow Relay to confer immediate benefits to in-licensing efforts, increasing both efficiency and effectiveness.
In-licensing groups using the Relay database can expect:
· Greater reach, with evaluation of technologies from over 500 University licensing offices and 2500 biotechnology companies
· Improved focus, with technologies of interest ranked by key licensing criteria
· Rapid go/no-go decisions limiting time and effort required by licensing teams
· Increased time spent on high-potential candidates
The result is a broader, deeper in-licensing program, making more efficient use of the existing business development group.